Нитросорбид

Quick links to important sections

Нитросорбид

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Нитросорбид

Overview: What is Нитросорбид?

Property Description
Active ingredient Isosorbide Dinitrate (ISDN)
Form Oral Tablet (Standard and Sublingual)
Pharmacological class Nitrate Vasodilator
Common use Management of heart-related chest discomfort
Origin Synthetic Organic Compound

Нитросорбид: Identity, Composition, and Pharmacological Class

Нитросорбид is a prescription medication whose active substance is isosorbide dinitrate (ISDN), a synthetic organic nitrate. This compound is classified pharmacologically as a Nitrate Vasodilator and acts as an Antianginal Agent. The clinical benefit of this chemical class is recognized for its effects on vascular tone, supporting its use in heart disease management protocols.

As a single-component product, Нитросорбид consists of the isosorbide dinitrate active ingredient combined with solid excipients to form its primary dosage form, which is the oral tablet. Being synthetic, the medicine is chemically synthesized rather than being derived from a natural source.


What is the General Purpose of Isosorbide Dinitrate?

The primary general purpose of isosorbide dinitrate is to reduce the workload on the heart and improve the oxygen balance in the heart muscle. It achieves this by functioning as a nitric oxide donor in the body, which signals the vascular smooth muscle to relax. This relaxation process, known as vasodilation, is particularly pronounced in the venous system, causing venodilation.

Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing pressure (preload). The medicine works by expanding the blood vessels to ease the heart's burden, a general effect used in the long-term prevention of recurrent chest discomfort.


How Do Different Forms of Нитросорбид Vary?

Нитросорбид is available in several oral tablet forms that differ mainly in their speed of absorption and duration of effect. The medication can be found in a standard oral form, which provides a long-acting and sustained therapeutic benefit, as well as a sublingual tablet intended for fast-acting use.

The difference in action time is governed by the formulation and the route of administration, specifically whether the tablet is swallowed or dissolved under the tongue. This distinction allows the drug to be used for either immediate needs or long-term preventative regimens, showcasing the medication's dual utility.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. Isosorbide - StatPearls - NCBI Bookshelf

What side effects are possible with Нитросорбид?

Possible Side Effects and Safety Information

The safety profile of Нитросорбид (Isosorbide Dinitrate) is documented in regulatory labeling by classification according to the frequency of occurrence and the affected organ system. This information is non-advisory and strictly descriptive of the officially listed adverse reactions.


Frequency and System-Organ Classes

The most frequent side effects, classified as Common (ge 1/100 to < 1/10) in regulatory documents, are primarily related to its blood vessel effects. These include headache, dizziness, asthenia (weakness), and orthostatic hypotension (a drop in blood pressure upon standing). These effects are categorized under Nervous System Disorders and Vascular Disorders.

Uncommon reactions (ge 1/1,000 to < 1/100) include gastrointestinal symptoms like nausea and vomiting, and allergic skin reactions. Rare but documented adverse effects classified as Very Rare (< 1/10,000) include severe skin reactions like Exfoliative dermatitis and Stevens-Johnson Syndrome.

Safety Patterns and Specific Considerations

Adverse effect patterns related to the timing of use are noted in the official profile. The headache is commonly observed to disappear after the first week or two of use as initial tolerance develops. Effects such as drops in blood pressure and orthostatic hypotension are more likely to occur with first-time administration or when the dosage is increased.

Serious adverse reactions documented in the label include circulatory collapse (sometimes associated with slow heart rhythm/bradyarrhythmia and fainting/syncope), as well as severe hypotension.

Safety notes for specific populations are included in regulatory texts. Caution is advised for older adults, and dose adjustment may be required, particularly in the presence of renal or hepatic impairment. The safety and efficacy of the medication have not been established in the paediatric population.

Overdose and Emergency Response

Overdose with Нитросорбид (Isosorbide Dinitrate) is officially documented to result from excessive vasodilation, which requires immediate medical intervention. The official regulatory advice mandates that individuals seek emergency medical attention for any suspected overexposure.

Documented Manifestations and Severe Outcomes

Category Official Regulatory Statement Focus
Documented overdose presentations Prompt and severe fall in blood pressure ( hypotension), persistent and throbbing headache, vertigo, syncope, confusion, and convulsions. Gastrointestinal symptoms such as nausea, vomiting, and bloody diarrhea are also noted.
Serious / life-threatening outcomes Circulatory collapse and methemoglobinemia are documented severe outcomes, with the latter presenting as cyanosis ( bluish-colored skin or lips) and difficulty breathing.

Emergency Actions and Management

Management is primarily symptomatic and supportive. The official guidance requires careful clinical or hemodynamic monitoring in a hospital setting due to the potential for severe hypotension and tachycardia. Treatment procedures include attempts to increase central fluid volume using intravenous normal saline or similar fluids, often accompanied by passive elevation of the patient’s legs. The use of epinephrine or other arterial vasoconstrictors to treat the associated hypotension is noted in labeling as likely to be detrimental.

The overall official overdose profile is defined by the immediate, severe cardiovascular effects, which is the basis for the regulatory mandate to contact emergency services immediately when overdose is suspected.

Therapeutic Uses of Нитросорбид

Managing Symptoms Associated with Ischemic Chest Discomfort and Recurrent Manifestations

Нитросорбид is commonly used in the management of angina pectoris, applied to address the characteristic chest discomfort, pressure, or tightness that can be linked to insufficient oxygen supply to the heart muscle (ischemia). The medication is considered relevant in the supportive management of symptoms related to long-term prevention in chronic heart conditions. Its applications are concentrated on managing symptoms associated with coronary artery disease.

The primary areas of relevance include managing symptoms associated with angina pectoris, contributing to long-term management of episodic ischemic pain, and offering adjunctive support for chronic and acute heart failure symptoms, such as pulmonary congestion.

“This medicine is relevant for easing symptoms associated with heightened physiological stress linked to cardiac insufficiency and may assist with managing the symptomatic distress of an acute episode.”

In its preventative role, the medication supports patients in maintaining functional stability during periods of increased physical activity, contributing to improved comfort against recurrent symptoms. Beyond its core use, it is also applied to address respiratory distress and fluid buildup when used as supportive therapy for heart failure. This supportive function may assist with managing symptoms that create noticeable physiological strain linked to cardiac insufficiency.

Quick Fact: Relief for Ischemic Symptoms
This medication is primarily relevant for easing chest discomfort that stems from a temporary lack of oxygen supply to the heart muscle.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Нитросорбид?

The eligibility for using Нитросорбид (Isosorbide Dinitrate) is strictly defined by regulatory documents, focusing on patient status and co-medications.


Absolute Contraindications

Use of this medicine is strictly prohibited (contraindicated) for patients with a known allergy to isosorbide dinitrate or any organic nitrates. It is also contraindicated for patients taking Phosphodiesterase Type 5 (PDE-5) Inhibitors (e.g., sildenafil, tadalafil) or the soluble guanylate cyclase (sGC) stimulator riociguat, due to the risk of severe hypotension.


Restricted Populations

Certain populations require explicit caution or special monitoring as specified in official labeling:

  • Organ Function: Caution is required for patients with severe hepatic (liver) or renal (kidney) impairment.
  • Age and Data: Safety and effectiveness are not established for the pediatric population. Older adults (65 and over) should use the medicine cautiously due to generally insufficient clinical data in this group.
  • Physiological Status: Use requires caution in individuals who are hypotensive, volume-depleted, or have hypertrophic cardiomyopathy.
  • Pregnancy/Lactation: Use during pregnancy or breastfeeding requires a determination that the potential benefit justifies the potential risk due to a lack of adequate data on the fetus or infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products: Official Regulatory Information

The interaction profile for Isosorbide Dinitrate (Нитросорбид) is largely structured around the potential for severe hypotensive effects, as documented in official regulatory labeling.

Formal Contraindicated Combinations

The co-administration of Isosorbide Dinitrate is absolutely contraindicated with certain medications due to the risk of profound, life-threatening drops in blood pressure and syncope. These include:

  • Phosphodiesterase type 5 (PDE5) Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil).
  • Soluble Guanylate Cyclase (GC) Stimulators (e.g., Riociguat).

Timing-based separation rules are mandatory for the use of nitrates following PDE5 inhibitor administration, requiring at least 24 to 48 hours depending on the specific inhibitor used.

Pharmacodynamic Interaction Risks

Co-administration with other blood pressure-lowering agents may result in additive hypotensive effects. This includes various classes of antihypertensive drugs, such as beta-blockers, calcium channel blockers, and diuretics, as well as Phenothiazines.

Interacting Substance Officially Documented Outcome
Alcohol (Ethanol) May enhance hypotensive effects, intensifying symptoms like dizziness.
Dihydroergotamine May increase the blood level of Dihydroergotamine.
Other Methemoglobinemia-Inducing Agents Increased risk or severity of methemoglobinemia.

Population-Specific Notes

Regulatory documents advise caution for dose selection in elderly patients and those with hepatic or renal impairment, reflecting increased sensitivity to drug effects and potential for altered clearance, which can impact interaction relevance.

Mechanism of Action

Molecular Mechanism: Nitric Oxide Activation Cascade

The action of Нитросорбид begins as it undergoes enzymatic bioactivation within the vascular smooth muscle cells, functioning as an exogenous Nitric Oxide ( NO) donor. The released NO is the active mediator that binds to and activates the enzyme soluble Guanylyl Cyclase ( sGC). This critical step rapidly increases levels of the secondary messenger cyclic Guanosine Monophosphate ( cGMP), initiating the cellular cascade that results in the relaxation of the vascular smooth muscle.


Physiological Effect: Predominant Preload Reduction

The molecular relaxation is translated into a systemic effect through vasodilation, where the effect is predominant in the venous capacitance vessels. This causes peripheral pooling of blood, which lowers the volume and pressure of blood returning to the heart (cardiac preload). This reduction in preload is the key physiological adjustment achieved by the mechanism, as it directly decreases the energy demand placed on the cardiac muscle.


Mechanistic Limitation: Bioactivation Capacity and Tolerance

The continued efficacy of the drug is dependent on the bioactivation pathway's capacity to convert the parent molecule into NO. Continuous exposure to the drug diminishes the necessary enzymatic co-factors required for NO release. This limitation leads to nitrate tolerance, a phenomenon where the molecular activation of the sGC- cGMP cascade is diminished, limiting the resulting vasodilatory response.

Dosage and Administration Information

How to Use Нитросорбид: Administration Guidelines

Нитросорбид, which contains isosorbide dinitrate, is administered through specific routes and schedules to manage its physiological effects and minimize tolerance. The routes of administration are oral (for standard and extended-release tablets), sublingual, and intravenous (IV) infusion in hospital settings.


Dosing and Frequency Patterns

The pattern of use is distinguished between rapid intervention and long-term maintenance. Standard oral doses typically range from 10 mg to 40 mg and are usually taken two or three times daily in divided doses. Extended-release formulations are commonly prescribed as 40 mg once daily. For acute needs, the sublingual tablet (5 mg to 10 mg) is placed under the tongue and allowed to dissolve, and may be repeated once after ten minutes. A critical feature of maintenance therapy is the required dose-free interval of at least 14 hours daily to prevent the development of drug tolerance.


Administration Requirements

Administration Type Procedural Instruction Population Rules
Oral (Extended-Release) Must be swallowed whole; the tablet or capsule should not be crushed, split, or chewed. Dosing for older adults should begin at the low end of the recommended range.
Sublingual Must be held under the tongue until fully dissolved; must not be swallowed or chewed. The medication's safety and efficacy are not established in the pediatric population.

IV administration requires dilution and use of specific, non-adsorbent tubing; the infusion rate is then adjusted based on the patient’s response.

Recent Clinical Evidence

Нитросорбид: Recent Clinical Evidence

Clinical evidence for Нитросорбид (known internationally as Isosorbide Dinitrate or ISDN) primarily focuses on its use in managing and preventing symptoms of Angina Pectoris (chest pain) due to coronary artery disease.


Efficacy in Angina Prophylaxis

Research studies, including randomized controlled trials (RCTs), have investigated the compound’s ability to affect exercise tolerance in patients with stable angina.

  • Single-Dose Trials: Controlled trials involving single oral doses of the compound have demonstrated an association with reduced exercise-related angina for a period of up to 8 hours following administration.
  • Multiple-Dose Trials: When the compound is taken in a multiple-dose regimen for several weeks, efficacy against angina has been reported; however, due to the potential for developing nitrate tolerance, the anti-anginal effect may be limited to a shorter duration (e.g., approximately two hours) after each dose. This highlights the importance of an appropriate daily dose-free interval to help maintain a response.

Research on Heart Failure and Combination Therapy

Research has also explored the compound's application in heart failure. Studies have examined its role, often in combination with other medications, as part of a multi-drug approach to managing congestive symptoms and improving hemodynamic parameters (such as reducing preload).

Research Area Focus of Study Key Measurement Indicators
Angina Management Effect on exertional chest pain Exercise duration, time to angina onset
Heart Failure Adjunct therapy role Left ventricular end-diastolic pressure, pulmonary capillary wedge pressure

Safety Profile Investigations

Clinical data indicates that the most commonly reported undesirable effects are related to the compound’s action as a vasodilator, including headache and low blood pressure (hypotension). These effects are consistently monitored across clinical trials to evaluate the compound's overall safety profile and tolerability during both short- and long-term use.

Frequently Asked Questions (FAQ)

Common questions about Нитросорбид (FAQ)

Q: What is the difference between Нитросорбид and Isosorbide Dinitrate?

A: Isosorbide Dinitrate is the active drug component recognized and referenced in official regulatory documents. Нитросорбид is a recognized brand or common name for the medicine that contains this active ingredient.

Q: What is the main medical purpose of Нитросорбид?

A: Regulatory documents state that the drug is indicated for the treatment and prevention of angina pectoris, which is chest pain related to coronary artery disease. Official information also notes its use alongside other medicines to manage congestive heart failure.

Q: What condition is Нитросорбид prescribed for most often?

A: The official labeling indicates that the drug is primarily prescribed for the treatment and prevention of angina pectoris (chest pain). It is also used as an adjunctive (supporting) treatment for congestive heart failure.

Q: Is Нитросорбид considered a type of heart medicine?

A: Yes, it is used for heart-related conditions. It is classified as a vasodilator, meaning it works by relaxing blood vessels throughout the body. This action is associated with treating and preventing conditions like angina pectoris and managing heart failure.

Q: Is Нитросорбид used to treat high blood pressure?

A: Official documentation indicates that the approved uses for this drug are for angina pectoris and heart failure. It is not listed as a primary or standard treatment for essential hypertension (high blood pressure).

Q: Is this drug the same as nitroglycerin?

A: Both medicines are classified as organic nitrates and function as vasodilators to treat angina. Regulatory documents state that the actions of Isosorbide Dinitrate are similar to nitroglycerin, but it is important to note that it has a slower onset of action.

Q: Can Нитросорбид be taken with food?

A: Official product information advises that the immediate-release tablets should be taken on an empty stomach. This requirement is typically met by allowing a period of time, such as at least 30 minutes before or 2 hours after, consuming food.

Q: Does the time of day matter when taking Нитросорбид?

A: The schedule is designed to include a daily dose-free interval to prevent the development of tolerance (where the drug loses its effectiveness). Official regulatory information indicates that careful timing of doses is necessary to manage effectiveness.

Q: Is it safe to stop taking Нитросорбид suddenly?

A: Regulatory documents generally advise against stopping the medication suddenly, noting that symptoms may worsen. Official information may describe a process for gradual reduction.

Q: Is Нитросорбид safe for older adults to use?

A: Regulatory labeling addresses the use of this drug in older adults. It advises that any dosing should begin at the low end of the recommended range, requiring careful observation during the initial treatment period.

Q: How quickly should Нитросорбид start working for chest pain?

A: The time it takes to start working depends on the formulation. Official information states the onset of action for the immediate-release oral tablet is approximately 30 minutes. The extended-release form has a significantly slower onset, typically taking 12 to 24 hours to begin its effect.

Q: How long do the effects of Нитросорбид typically last after taking it?

A: The drug’s long-term effectiveness is managed by following a schedule that includes a daily dose-free interval. The major biologically active component, isosorbide mononitrate, is generally described as having a duration of action of approximately 6 to 10 hours.

Q: What are the most commonly reported side effects of Нитросорбид?

A: According to official product information, the most frequently reported side effect is a headache, which is classified as 'very common.' Other common side effects include hypotension (low blood pressure) and dizziness.

Q: Why do people often report headaches after taking Нитросорбид?

A: Headaches are a very common side effect and are considered a common marker of the drug's activity in the body, which involves widening blood vessels (vasodilation). Official information notes that the incidence of headaches often diminishes with continued use.

Q: Is dizziness a common side effect of Нитросорбид?

A: Yes, dizziness and light-headedness (often related to positional changes) are listed as common side effects. They are most likely to occur at the start of therapy or following an increase in dosage.

Q: Does Нитросорбид affect vision or eyes?

A: Blurred vision is a reported side effect of the medicine. Official information states that patients with angle-closure glaucoma are advised to be monitored carefully when the medicine is used.

Q: Are there any known long-term side effects from using Нитросорбид?

A: Official labeling mentions that in industrial workers exposed to high doses over long periods, evidence of true physical dependence has been noted. This dependence is a physical reliance on the drug, which can lead to temporary withdrawal symptoms if the medication is stopped suddenly.

Q: Is it normal to feel flush or warm after taking the medicine?

A: Yes, a sensation of flushing or warmth is listed in official documents as an uncommon side effect. It may occur as the body adjusts to the medication, especially at the start of treatment.

Q: Can Нитросорбид cause problems with the liver or kidneys?

A: Official labeling advises that the drug should be used with caution in patients with pre-existing severe hepatic (liver) or renal (kidney) impairment. This is because these organs are involved in clearing the drug from the body.

Q: Is there a risk of developing a dependency on Нитросорбид?

A: Regulatory documents state that true physical dependence has been observed in specific circumstances, such as long-term, high-dose occupational exposure. This is a physical reliance on the drug, which is distinct from psychological addiction.

Q: What symptoms are described as signs of a serious adverse reaction?

A: Symptoms associated with a severe hypotensive response (extremely low blood pressure) include nausea, vomiting, paleness, excessive sweating, and collapse (sometimes with fainting). These symptoms are described in regulatory documents as signs of a severe reaction.

Q: Is fainting listed as a possible side effect?

A: Yes, syncope (fainting) is a reported symptom. This may occur if the drug causes significant postural hypotension (low blood pressure upon standing) or triggers a severe hypotensive response.

Q: Can Нитросорбид affect sleep patterns?

A: While there is no direct evidence of a change in sleep patterns, official labeling lists potential side effects like tiredness and dizziness. These effects could indirectly influence daily activity and rest.

Q: What common medicines must not be taken with Нитросорбид?

A: The drug is contraindicated (not permitted for use) with specific other medicines. This includes all phosphodiesterase inhibitors (e.g., sildenafil, tadalafil) and riociguat (a soluble guanylate cyclase stimulator).

Q: How does alcohol interact with the effects of Нитросорбид?

A: Official product information states that alcohol exhibits additive vasodilating effects when used with this drug. This means the combination may lead to an increased risk of side effects like light-headedness, dizziness, and fainting due to lowered blood pressure.

Q: Can over-the-counter pain relievers interact with Нитросорбид?

A: Regulatory information indicates that common pain relievers such as aspirin and/or acetaminophen may be used to help relieve the headaches that the drug can cause, without being reported to affect the drug's efficacy.

Q: Are there special considerations for pregnant women taking Нитросорбид?

A: Official labeling advises that the drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. This precaution is based on the lack of adequate, well-controlled studies in pregnant women.

Q: What are the general criteria for who cannot use Нитросорбид?

A: General criteria for contraindication include a known allergy to the drug or any of its components. Additionally, the drug must not be used by individuals taking phosphodiesterase inhibitors (e.g., sildenafil) or riociguat.

Q: Are there warnings for people with specific types of low blood pressure?

A: Yes, regulatory information advises that the drug should be used with caution in patients who are already hypotensive (have low blood pressure) or who are volume depleted (lacking sufficient body fluid or blood volume).

Q: What are the main differences between Нитросорбид and Isosorbide Mononitrate?

A: Isosorbide mononitrate is described as the major biologically active metabolite (a substance created when the body breaks down the drug) of Isosorbide Dinitrate. Formulations containing the mononitrate typically have a longer duration of action.

Q: Why would a doctor prescribe Нитросорбид instead of Nitroglycerin?

A: Regulatory information indicates that because the onset of action of Isosorbide Dinitrate is not rapid enough to abort an acute anginal event (sudden, severe chest pain). Therefore, the drug is typically used for prevention or maintenance, while other nitrates like nitroglycerin are generally preferred for immediate relief.

Q: Is Нитросорбид considered an old or new type of treatment?

A: The drug is considered a long-established, core medication. It is listed on the World Health Organization's List of Essential Medicines and was first written about in 1939, indicating its history and importance in clinical medicine.

How should Нитросорбид be stored and disposed of?

Official Storage and Disposal Requirements

Isosorbide dinitrate (Нитросорбид) must be stored under specific environmental and container conditions as documented in official regulatory labeling.

Storage Constraints

The medication must be stored at controlled room temperature, generally between 15 C and 30 C (59 F and 86 F). It is essential to keep the product from freezing and to store it away from heat, moisture, and direct light.

The tablets must remain in their original, tightly closed container and must be kept out of the reach of children.

Disposal Instructions

Unused or expired medication should not be kept. Disposal must be conducted in accordance with local regulations as advised by a healthcare professional. Regulatory guidance advises against discarding the product into sewers or surface water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Нитросорбид found in:

A-Z Index: